BAIN CAPITAL LIFE SCIENCES INVESTORS LLC
Q1 2024 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001703031
· Institutional investment manager
Consolidated report · includes
14 managers
since Q1 2021
$1.2B Reported Value Total
Reported value
$1.2B
Quarter over quarter
+22.9%
Holdings
26
Top-10 concentration
81.8%
Reports holdings for
- Bain Capital Life Sciences Opportunities IV, L.P. (not a 13F filer in our records) · File #028-26575 · since Q1 2026 · declared by one filing
- Bain Capital Life Sciences Opportunities IV GP, LLC (not a 13F filer in our records) · File #028-26576 · since Q1 2026 · declared by one filing
- Bain Capital Life Sciences Fund IV, L.P. (not a 13F filer in our records) · File #028-26577 · since Q1 2026 · declared by one filing
- Bain Capital Life Sciences IV General Partner, LLC (not a 13F filer in our records) · File #028-26578 · since Q1 2026 · declared by one filing
- Bain Capital Life Sciences Fund II, L.P. (not a 13F filer in our records) · File #28-20814 · since Q1 2021 · declared by one filing
- Bain Capital Life Sciences Investors II, LLC (not a 13F filer in our records) · File #28-20816 · since Q1 2021 · declared by one filing
- Bain Capital Life Sciences Opportunities III, LP (not a 13F filer in our records) · File #28-22966 · since Q1 2023 · declared by one filing
- Bain Capital Life Sciences Opportunities III GP, LLC (not a 13F filer in our records) · File #28-22968 · since Q1 2023 · declared by one filing
- Bain Capital Life Sciences III General Partner, LLC (not a 13F filer in our records) · File #28-22975 · since Q1 2023 · declared by one filing
- BCLS II Investco (GP), LLC (not a 13F filer in our records) · File #28-22976 · since Q1 2023 · declared by one filing
- BCLS II Investco, LP (not a 13F filer in our records) · File #28-22978 · since Q1 2023 · declared by one filing
- Bain Capital Life Sciences Fund III, L.P. (not a 13F filer in our records) · File #28-22979 · since Q1 2023 · declared by one filing
- BCLS Fund III Investments GP, LLC (not a 13F filer in our records) · File #28-25138 · since Q1 2025 · declared by one filing
- BCLS Fund III Investments, LP (not a 13F filer in our records) · File #28-25140 · since Q1 2025 · declared by one filing
- Bain Capital Life Sciences Fund IV, L.P. (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
- Bain Capital Life Sciences IV General Partner, LLC (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
- Bain Capital Life Sciences Opportunities IV GP, LLC (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
- Bain Capital Life Sciences Opportunities IV, L.P. (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
- Bain Capital Life Sciences Partners, LP (not a 13F filer in our records) · File #28-18476 · Q1 2018 – Q3 2025 · declared by one filing
- Bain Capital Life Sciences Fund, L.P. (not a 13F filer in our records) · File #28-18478 · Q1 2018 – Q3 2025 · declared by one filing
- BCLS Fund III Investments GP, LLC (not a 13F filer in our records) · Q4 2024 – Q4 2024 · declared by one filing
- BCLS Fund III Investments, LP (not a 13F filer in our records) · Q4 2024 – Q4 2024 · declared by one filing
- BC SW, LP (not a 13F filer in our records) · File #28-20270 · Q2 2020 – Q3 2024 · declared by one filing
- Bain Capital Life Sciences Fund III, L.P. (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
- Bain Capital Life Sciences III General Partner, LLC (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
- Bain Capital Life Sciences Opportunities III GP, LLC (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
- Bain Capital Life Sciences Opportunities III, LP (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
- BCLS II Investco (GP), LLC (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
- BCLS II Investco, LP (not a 13F filer in our records) · Q4 2022 – Q4 2022 · declared by one filing
- BCIP Life Sciences Associates, LP (not a 13F filer in our records) · File #28-21927 · Q1 2022 – Q3 2022 · declared by one filing
- BCIP Life Sciences Associates, LP (not a 13F filer in our records) · Q4 2021 – Q4 2021 · declared by one filing
- Bain Capital Life Sciences Fund II, L.P. (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing
- Bain Capital Life Sciences Investors II, LLC (not a 13F filer in our records) · Q4 2020 – Q4 2020 · declared by one filing
- Bain Capital Life Sciences Partners, LP (not a 13F filer in our records) · File #028-18476 · Q1 2020 – Q1 2020 · declared by one filing
- BC SW, LP (not a 13F filer in our records) · Q1 2020 – Q1 2020 · declared by one filing
- Bain Capital Life Sciences Fund, L.P. (not a 13F filer in our records) · Q4 2017 – Q4 2017 · declared by one filing
- Bain Capital Life Sciences Partners, LP (not a 13F filer in our records) · Q4 2017 – Q4 2017 · declared by one filing
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Adam Koppel
Partner of Bain Capital Life Sciences Investors, LLC
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2024 13F record
Q1 2024 13F filing summary
| Period of report | March 31, 2024 |
|---|---|
| Filed | May 15, 2024 |
| Form | 13F-HR |
| Reported value | $1.2B |
| Positions | 26 |
| Change in reported value | +19.3% |
| New positions | 2 |
| Exited positions | 3 |
| Position turnover | 17.2% |
| Top-10 concentration | 81.8% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
21 | $1.7B |
|
Q1 2026 13F
Filed May 15, 2026
|
20 | $1.1B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
19 | $1.3B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
21 | $1.5B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
23 | $799.3M |
|
Q1 2025 13F
Filed May 15, 2025
|
24 | $675.9M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
26 | $850.1M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
24 | $961.2M |
|
Q2 2024 13F
Filed Aug 12, 2024
|
25 | $910.8M |
|
Q1 2024 13F
Filed May 15, 2024
|
26 | $1.2B |
|
Q4 2023 13F
Filed Feb 13, 2024
|
27 | $1.0B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
31 | $894.2M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
32 | $971.0M |
|
Q1 2023 13F
Filed May 15, 2023
|
34 | $800.1M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
33 | $894.8M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
33 | $837.8M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
35 | $852.7M |
|
Q1 2022 13F
Filed May 16, 2022
|
34 | $1.0B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
34 | $1.3B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
33 | $1.6B |
15 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | NAMS NEWAMSTERDAM PHARMA COMPANY | $247.7M | 19.91% |
| 2 | NUVL NUVALENT INC | $202.5M | 16.28% |
| 3 | DNTH DIANTHUS THERAPEUTICS INC | $89.8M | 7.21% |
| 4 | IRON DISC MEDICINE INC | $82.0M | 6.59% |
| 5 | KYTX KYVERNA THERAPEUTICS INC | $78.6M | 6.32% |
| 6 | PHVS PHARVARIS N V | $76.3M | 6.14% |
| 7 | SVRA SAVARA INC | $72.5M | 5.83% |
| 8 | ANNX ANNEXON INC | $62.4M | 5.02% |
| 9 | SLDB SOLID BIOSCIENCES INC | $53.7M | 4.32% |
| 10 | MDGL MADRIGAL PHARMACEUTICALS INC | $52.6M | 4.23% |
| 11 | MRSN MERSANA THERAPEUTICS INC | $38.8M | 3.12% |
| 12 | CABA CABALETTA BIO INC | $27.6M | 2.22% |
| 13 | XFOR X4 PHARMACEUTICALS INC | $23.5M | 1.89% |
| 14 | TNGX TANGO THERAPEUTICS INC | $23.0M | 1.85% |
| 15 | ARQT ARCUTIS BIOTHERAPEUTICS INC | $19.9M | 1.6% |
| 16 | NRIX NURIX THERAPEUTICS INC | $16.6M | 1.34% |
| 17 | SYRS SYROS PHARMACEUTICALS INC | $14.7M | 1.18% |
| 18 | MRNS MARINUS PHARMACEUTICALS INC | $12.6M | 1.01% |
| 19 | AVIR ATEA PHARMACEUTICALS INC | $10.0M | 0.81% |
| 20 | CCCC C4 THERAPEUTICS INC | $9.3M | 0.75% |
Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.